Liquidia Corp LQDA

Healthcare

Liquidia Corporation is a biopharmaceutical company. The Company is focused on the development, manufacture and commercialization of products that address unmet patient needs, with a focus directed towards rare cardiopulmonary diseases, such as pulmonaryarterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The Company operates through its wholly owned operating subsidiaries, Liquidia Technologies, Inc. and Liquidia PAH, LLC. Its proprietary PRINT technology is a particle engineering platform, which enable precise production of uniform drug particles. Its lead product candidate is YUTREPIA for the treatment of PAH and PH-ILD. YUTREPIA is an inhaled dry powder formulation of treprostinil designed with PRINT to improve the therapeutic profile of treprostinil by enhancing deep lung delivery while using a convenient, dry-powder inhaler (DPI) and by achieving higher dose levels than the labeled doses of current inhaled therapies.

NDAQ:LQDA - Post by User

Liquidia Corp

<< Previous

Bullboard Posts

Post by whytestockson Jan 25, 2024 9:15pm

59 Views

Post# 35846300

Liquidia Corporation Provides Update on New Drug Application

Just In: $LQDA Liquidia Corporation Provides Update on New Drug Application for YUTREPIA(TM) (treprostinil) inhalation powderMORRISVILLE, N.C., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (the Company) (NASDAQ: LQDA) announced today that the U.S. Food and Drug Administration (FDA) provided an update on its review of the New Drug Application (NDA) for YUTREPIA™ (treprostinil) inhalation powder to treat...LQDA - Liquidia Corporation Provides Update on New Drug Application for YUTREPIA(TM) (treprostinil) inhalation powder

<< Previous

Bullboard Posts

Nine Mile Metals completes acquisition of 3 properties